<DOC>
	<DOCNO>NCT00506311</DOCNO>
	<brief_summary>Primary Objective : 1 . To determine whether use fibrin sealant apply superficial groin soft tissue follow node dissection result decrease cumulative postoperative drainage , early drain removal , low incidence seroma . Secondary Objectives : 1 . To determine postoperative morbidity rate use fibrin sealant follow superficial groin dissection . 2 . To assess patient-valuation outcome perform cost-benefit analysis use willingness-to-pay model . 3 . To determine serum level , lymphatic fluid level , cutaneous expression vascular endothelial growth factor-D ( VEGF-D ) , vascular endothelial growth factor-C ( VEGF-C ) receptor , vascular endothelial growth factor receptor-3 ( VEGFR-3 ) correlate nodal tumor burden development lymphedema patient melanoma .</brief_summary>
	<brief_title>Evaluating Use Fibrin Tissue Adhesive Melanoma Patients</brief_title>
	<detailed_description>Patients study schedule groin dissection part surgery treatment melanoma . Within 2 week entry study , patient complete physical exam medical history . These patient randomly assign ( toss coin ) one two group . Patients one group receive TISSEEL apply externally dissect groin area . Patients group receive fibrin sealant . For patient admitted hospital , surgical site monitor surgeon evidence wound complication first 24 hour surgery . At time discharge hospital , patient instruct drain care measure drainage day drain remove . The content drain collected patient first day surgery , first return follow-up visit M.D . Anderson Cancer Center , drain removal . Follow-up wound exam perform local primary physician M.D . Anderson Melanoma Clinic 1-4 week 6 week surgery . Participation 6-week follow-up . This investigational study . The sealant FDA approve , though use study experimental . About 58 patient take part study . All enrol M. D. Anderson .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Fibrin Tissue Adhesive</mesh_term>
	<criteria>Part I Inclusion Criteria Patients consent participate . Patients melanoma undergone superficial node dissection ( without concurrent deep ( ilioinguinal ) node dissection within last six month part surgical treatment consider study . Part II Inclusion Criteria Patients consent participate . Patients melanoma superficial node dissection indicate ( without concurrent deep ( ilioinguinal ) node dissection . Part II Exclusion Criteria Patients know hypersensitivity bovine protein . Patient undergone prior radiation therapy operative site ( groin ) . Patient pregnant lactating . Patient steroid dependent within last 6 month . Patient use aspirin antiplatelet drug ( exclude Celebrex ) within seven day operation . Patients preexist lymphedema . Patients preexist medical condition per discretion principal investigator .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Superficial Groin Dissection</keyword>
	<keyword>Melanoma</keyword>
	<keyword>Fibrin Tissue Adhesive</keyword>
	<keyword>Fibrin Sealant</keyword>
	<keyword>Tisseel</keyword>
	<keyword>Seroma</keyword>
</DOC>